Increased donor inhibitory KIR with known HLA interactions provide protection from relapse following HLA matched unrelated donor HCT for AML

[1]  Bijal A. Parikh,et al.  Control of Viral Infection by Natural Killer Cell Inhibitory Receptors , 2020, Cell reports.

[2]  S. Vidal,et al.  Mechanisms of Natural Killer Cell Evasion Through Viral Adaptation. , 2020, Annual review of immunology.

[3]  Jeffrey S. Miller,et al.  Investigation of donor KIR content and matching in children undergoing hematopoietic cell transplantation for acute leukemia. , 2020, Blood advances.

[4]  P. Parham,et al.  KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation. , 2020, Blood advances.

[5]  V. Lange,et al.  External Validation of Models for KIR2DS1/KIR3DL1-informed Selection of Hematopoietic Cell Donors fails. , 2020, Blood.

[6]  Yu Wang,et al.  Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation. , 2019, Blood advances.

[7]  Shasha Chen,et al.  Synergized regulation of NK cell education by NKG2A and specific Ly49 family members , 2019, Nature Communications.

[8]  N. Kröger,et al.  Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin , 2019, Haematologica.

[9]  B. Ebert,et al.  Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation. , 2019, Blood advances.

[10]  R. Sabo,et al.  Killer Immunoglobulin-like Receptor-Ligand Interactions Predict Clinical Outcomes Following Unrelated Donor Transplants , 2019, bioRxiv.

[11]  Fares Alahdab,et al.  Choosing a Reduced-Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation, Fludarabine/Busulfan versus Fludarabine Melphalan: A Systematic Review and Meta-Analysis. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  P. Parham,et al.  Two to Tango: Co-evolution of Hominid Natural Killer Cell Receptors and MHC , 2019, Front. Immunol..

[13]  P. Parham,et al.  KIR Donor Selection: Feasibility in Identifying better Donors. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  B. Cho,et al.  Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  H. Deeg,et al.  Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity. , 2018, Blood advances.

[16]  H. Favoreel,et al.  Herpesvirus Evasion of Natural Killer Cells , 2018, Journal of Virology.

[17]  P. Parham,et al.  Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation. , 2018, Blood.

[18]  J. Kanda,et al.  Homozygous HLA-C1 is Associated with Reduced Risk of Relapse after HLA-Matched Transplantation in Patients with Myeloid Leukemia. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[19]  F. Appelbaum,et al.  Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[20]  Sarah E. Jackson,et al.  CMV immune evasion and manipulation of the immune system with aging , 2017, GeroScience.

[21]  S. Machherndl-Spandl,et al.  HLA-C KIR-Ligands Determine the Impact of Anti-Thymocyte Globulin (ATG) on Graft versus Host and Graft versus Leukemia Effects Following Hematopoietic Stem Cell Transplantation , 2017, Biomedicines.

[22]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[23]  K. Rezvani,et al.  Immune reconstitution post allogeneic transplant and the impact of immune recovery on the risk of infection , 2016, Virulence.

[24]  J. Storek,et al.  Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation , 2016, PloS one.

[25]  R. Schlenk.  Post-remission therapy for acute myeloid leukemia , 2014, Haematologica.

[26]  J. Klein,et al.  Donor Killer Cell Ig-like Receptor B Haplotypes, Recipient HLA-C1, and HLA-C Mismatch Enhance the Clinical Benefit of Unrelated Transplantation for Acute Myelogenous Leukemia , 2014, The Journal of Immunology.

[27]  F. Hentges,et al.  NK Cell Killer Ig-like Receptor Repertoire Acquisition and Maturation Are Strongly Modulated by HLA Class I Molecules , 2014, The Journal of Immunology.

[28]  K. Campbell,et al.  Natural killer cell biology: an update and future directions. , 2013, The Journal of allergy and clinical immunology.

[29]  J. Chewning,et al.  NK Cell Tolerance of Self-Specific Activating Receptor KIR2DS1 in Individuals with Cognate HLA-C2 Ligand , 2013, The Journal of Immunology.

[30]  J. Chewning,et al.  HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. , 2012, The New England journal of medicine.

[31]  B. Seliger,et al.  Clonal Evolution Including Partial Loss of Human Leukocyte Antigen Genes Favoring Extramedullary Acute Myeloid Leukemia Relapse After Matched Related Allogeneic Hematopoietic Stem Cell Transplantation , 2012, Transplantation.

[32]  Marcela R. Uribe,et al.  Donor KIR Genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[33]  W. Hwang,et al.  Effect of missing killer-immunoglobulin-like receptor ligand in recipients undergoing HLA full matched, non-T-depleted sibling donor transplantation: a single institution experience of 151 Asian patients , 2010, Bone Marrow Transplantation.

[34]  H. Ljunggren,et al.  NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation. , 2010, Blood.

[35]  H. Ulmer,et al.  The role of missing killer cell immunoglobulin-like receptor ligands in T cell replete peripheral blood stem cell transplantation from HLA-identical siblings. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[36]  D. Blaise,et al.  Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[37]  R. Negrin,et al.  Natural killer cells in allogeneic transplantation: effect on engraftment, graft- versus-tumor, and graft-versus-host responses. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[38]  F. Claas,et al.  Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells , 2009, Cancer Immunology, Immunotherapy.

[39]  Sofia Johansson,et al.  The strength of inhibitory input during education quantitatively tunes the functional responsiveness of individual natural killer cells. , 2009, Blood.

[40]  Eric O Long.  Negative signaling by inhibitory receptors: the NK cell paradigm , 2008, Immunological reviews.

[41]  Eric O Long,et al.  Line of attack: NK cell specificity and integration of signals. , 2008, Current opinion in immunology.

[42]  P. Parham,et al.  Synergistic Polymorphism at Two Positions Distal to the Ligand-Binding Site Makes KIR2DL2 a Stronger Receptor for HLA-C Than KIR2DL31 , 2008, The Journal of Immunology.

[43]  P. Tomasec,et al.  Modulation of natural killer cells by human cytomegalovirus. , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[44]  J. Piccirillo,et al.  HLA alleles determine differences in human natural killer cell responsiveness and potency , 2008, Proceedings of the National Academy of Sciences.

[45]  J. Chewning,et al.  Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands , 2007, The Journal of Immunology.

[46]  J. Chewning,et al.  Hierarchy of the Human Natural Killer Cell Response Is Determined by Class and Quantity of Inhibitory Receptors for Self-HLA-B and HLA-C Ligands1 , 2007, The Journal of Immunology.

[47]  G. Gastl,et al.  Impact of natural killer cell dose and donor killer‐cell immunoglobulin‐like receptor (KIR) genotype on outcome following human leucocyte antigen‐identical haematopoietic stem cell transplantation , 2007, Clinical and experimental immunology.

[48]  J. Klein,et al.  Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. , 2007, Blood.

[49]  R. Schots,et al.  A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation , 2005, Leukemia.

[50]  C. Craddock,et al.  The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. , 2004, Blood.

[51]  É. Vivier,et al.  Natural Killer Cells , 2016, Current Topics in Microbiology and Immunology.